Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-04-09
2010-11-02
Anderson, Rebecca L (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S255050, C514S278000, C514S372000, C514S374000, C514S237200, C514S256000, C514S397000, C514S406000, C514S381000, C514S275000, C548S408000, C548S214000, C548S216000, C548S300700, C548S357500, C548S253000, C544S230000, C544S070000, C546S015000
Reexamination Certificate
active
07825152
ABSTRACT:
The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of human diseases.
REFERENCES:
patent: 6894072 (2005-05-01), Arasappan et al.
patent: 7244721 (2007-07-01), Saksena et al.
patent: 2003/0216325 (2003-11-01), Saksena et al.
patent: 2005/0197301 (2005-09-01), Njoroge et al.
patent: 2005/0209164 (2005-09-01), Bogen et al.
patent: 2005/0249702 (2005-11-01), Njoroge et al.
patent: 2006/0046956 (2006-03-01), Sannigrahi et al.
patent: 2006/0281689 (2006-12-01), Malcolm
patent: 2007/0049536 (2007-03-01), Venkatraman et al.
patent: 2007/0093430 (2007-04-01), Chen et al.
patent: 2002008244 (2002-01-01), None
patent: WO 0208244 (2002-01-01), None
patent: 0218369 (2002-03-01), None
patent: 2003062265 (2003-07-01), None
patent: WO 03062265 (2003-07-01), None
patent: 2004113295 (2004-12-01), None
patent: 2005021584 (2005-03-01), None
patent: 2005028502 (2005-03-01), None
patent: 2005035525 (2005-04-01), None
patent: 2005042020 (2005-05-01), None
patent: 2005058821 (2005-06-01), None
patent: 2005077969 (2005-08-01), None
patent: 2005085242 (2005-09-01), None
patent: 2005085275 (2005-09-01), None
patent: 2005087731 (2005-09-01), None
patent: 2005123076 (2005-12-01), None
patent: 2006039488 (2006-04-01), None
patent: 2006050250 (2006-05-01), None
patent: 2006130553 (2006-12-01), None
patent: 2006130666 (2006-12-01), None
patent: 2006130686 (2006-12-01), None
patent: 2006130687 (2006-12-01), None
patent: 2007005838 (2007-01-01), None
patent: 2007016589 (2007-02-01), None
patent: 2007025307 (2007-03-01), None
patent: 2007120595 (2007-10-01), None
patent: 2007121124 (2007-10-01), None
patent: 2007121125 (2007-10-01), None
patent: WO 2007/133865 (2007-11-01), None
Arasappan et al. Tet. Lett. 2007, 48, 6343-6347.
Chen, Kevin X. et al.: “Novel Potent Hepatitis C Virus NS3 Serine Protease Inhibitors Derived from Proline-Based Macrocycles”, J. Med. Chem., 2006, 995-1005; vol. 49 (3). Published on Web Jan. 7, 2006.
Chen, Kevin X. et al.; “Potent 7-hydroxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid-based macrocyclic inhibitors of hepatitis C virus NS3 protease”, Journal of Medicinal Chemistry, Jun. 3, 2005 (Pub. 2006); pp. 567-574; vol. 49 (2).
Chen, Kevin X. et al.; “Proline-based macrocyclic inhibitors of the hepatitis C virus: Stereoselective synthesis and biological activity”; Angewandte Chemie, International Edition; 2005, pp. 7024-7028; vol. 44 (43).
Bogen, S. et al.; “Hepatitis C virus NS3-4A serine protease inhibitors: Use of a P2-P1 cyclopropyl alanine combination for improved potency”: Bioorganic & Medicinal Chemistry Letters; 2005: pp. 4515-4519; vol. 15 (20).
Chen, Kevin X. et al. “Synthesis and biological activity of macrocyclic inhibitors of hepatitis C virus (HCV) NS3 protease” Bioorganic & Medicianal Chemistry Letters; May 13, 2005 (Pub. Aug. 19, 2005), pp. 4475-4478, vol. 15 (20).
Arasappan, A. et al. “Hepatitis C virus NS3-4A serine protease inhibitors: SAR of P'2 moiety with improved potency”, Bioorganic & Medicinal Chemistry Letters, 2005, pp. 4180-4184, vol. 15(19).
Venkatraman, Srikanth et al. “Design and synthesis of depeptidized macrocyclic inhibitors of hepatitis C NS3-4A Protease Using structure-based drug design” Journal Medicinal Chemistry, 2005, pp. 5088-5091, vol. 48(16).
Arasappan, A. et al. “Novel 2-oxoimidazolidine-4-carboxylic acid derivatives as hepatitis C virus NS3-4A serine protease inhibitors: synthesis, activity, and X-ray crystal structure of an enzyme inhibitor complex”, Bioorganic & Medicinal Chemistry Letters, 2004, pp. 5751-5755, vol. 14(23).
Tsantrizos, Youla et al. “Olefin ring-closing metathesis as a powerful tool in drug discovery and development-potent macrocyclic inhibitors of the hepatitis C virus NS3 protease” Journal of Orgnaomettalic Chemistry, 2006, pp. 5163-5171, vol. 691 (24-25).
Llinas-Brunet, Montse et al.; “Structure-Activity Study on a Novel Series of Macrocyclic Inhibitors of the Hepatitis C Virus NS3 Protease Leading to the Discovery of BILN 2061”, Journal of Medicinal Chemistry, 2004, pp. 1605-1608, vol. 47(7).
Lamarre, Daniel et al. “An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus”, Nature Letters (London), 2003, pp. 186-189, vol. 426 (6963).
Tsantrizos, Youla S. et al. “Macrocyclic inhibitors of the NS3 protease as potential therapeutic agents of hepatitis C virus infection”, Angewandte chemie, International Edition, 2003, pp. 1356-1360, vol. 42(12).
Robert, Ronn et al. “Exploration of acyl sulfonamides as carboxylic acid replacements in protease inhibitors of the hepatitis C virus full-length NS3”, Bioorganic & Medicinal Chemistry, 2006, pp. 544-559, vol. 14(2).
Malancona, Savina et al. “SAR and pharmacokinetic studies on penethylamide inhibitors of the hepatitis C virus NS3/NS4A serine protease”, Bioorganic & Medicinal chemistry Letters, 2004, pp. 4575-4579, vol. 14(17).
Frutos, Rogelio P. et al. “Practical synthesis of 2[2-lsopropylaminothiazol-4-yl]-7-methoxy-1H-quinolin-4-one; key intermediate for the synthesis of potent HCV NS3 protease inhibitor BILN 2061”, 2006, Synthesis, pp. 2563-2567, vol.
Yee, Nathan K. et al., “Efficient Large-Scale Synthesis of BILN 2061 a potent HCV protease inhibitor by a convergent approach based on ring-closing metathesis”, 2006, Journal of Organic Chemistry, pp. 7133-7145, vol. 71(19).
Beaulieu, Pierrre L. et al., “Synthesis of (1R,2S)-1-Amino-2-vinylcyclopropanecarboxylic acid vinyl-ACCA) Derivatives: Key intermediates for the preparation of inhibitors of the hepatitis C virus NS3 protease”, Journal of Organic Chemistry, 2005, pp. 5869-5879, vol. 70 (15).
LaPlante, Steven R. et al., “Dynamics and structure-based design of drugs targeting the critical serine protease of the hepatitis C virus—from a peptidic substrate to BILN 2061”, Current Medicinal Chemistry: Anti-Infective Agents, 2005, pp. 111-132, vol. 4(2).
Liinas-Brunet, Montse et al. “A systematic approach to the optimization of substrate-based inhibitors of the hepatitis C virus NS3 protease: discovery of potent and specific tripeptide inhibitors”, Journal of Medicinal Chemistry, 2004, pp. 6584-6594, vol. 47(26).
Goudreau, Nathalie et al. “Potent inhibitors of the hepatitis C virus NS3 protease: design and synthesis of macrocyclic substrate-based Beta-strand mimics”, Journal of Organic Chemistry, 2004, pp. 6185-6201, vol. 69(19).
Faucher, Anne-Marie et al., “Synthesis of BILN 2061, an HCV NS3 protease inhibitor with proven antiviral effect in humans”, Organic Letters, 2004, pp. 2901-2904, vol. 6(17).
Lin, Kai et al., “Combination of Hepatitis C Virus NS3-NS4A protease inhibitor and alpha interferon synergistically inhibits viral RNA replication and facilities viral RNA clearance in replicon cells”, Antimicrobial Agents and Chemotherapy, 2004, pp. 4784-4792, vol. 48(12).
Perni, Robert B. et al., “Inhibitors of Hepatitis C virus NS3-4A protease. Effect of P4 capping groups on inhibitory potency and pharmacokinetics”, Bioorganic and Medicinal Chemistry Letters, 2007, pp. 3406-3411, vol. 17(12).
Thomson, John A. et al., “Hepatitis C virus NS3.4A protease inhibitors: countering viral subversion in vitro and showing promise in the clinic”, Current Opinion in Drug Discovery & Development,2006, pp. 606-617, vol. 9(5).
Perni, Robert B. et al. “Inhibitors of hepatitis C virus NS3-4A protease 2. Warhead SAR and optimization” Bioorganic & medicinal Chemistry Letters, 2004, pp. 1441-1446, vol. 14(6).
Lin, C. et al., “Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.bul.4A serine protease”, Infectious Disorders: Drug Targets, 2006, pp. 3-16, vol. 6(1).
Venkatraman, Srikanth et al., &
Brandl Trixi
Fu Jiping
Lenoir Francois
Parker David Thomas
Patane Michael
Alexander John
Anderson Rebecca L
Coughlin Matthew P
Novartis AG
LandOfFree
Organic compounds and their uses does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Organic compounds and their uses, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Organic compounds and their uses will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4218282